Dioseve
Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden
$7MSeries A+
Role not disclosedActivity from announced rounds
Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy